linjc16/ctgov huggingface dataset:
Surviving a Decade or More After Coronary Revascularization in a Middle Eastern Population

Study Overview
=================
Brief Summary
-----------------
The study will look at the cardiovascular risk factors as they arise, as well at the need for further revascularization after at least 10 years of coronary revascularization in Middle Eastern patients. The PI will overlook the whole process. Dr Ahmad Tamari, the assistant to the PI will asses this whole process of data collection, management and manuscript drafting.

Detailed Description
-----------------
Middle Eastern patients aged 18 years or above presenting to cardiology service at one tertiary care center who had coronary revascularization (stent or coronary bypass surgery, i.e., index procedure) at least 10 years back, will interviewed to determine: Evolution of cardiovascular risk factors in the period from index procedure to time of interview. These risk factors include; hypertension, diabetes, smoking, dyslipidemia and obesity. Need for further arterial revascularization from the index procedure to time of interview. These arterial revascularization procedures include A. Coronary: stent and/or bypass surgery B. Carotid endarterectomy. C. peripheral arterial revascularization D. Renal artery stent. Medications used at the time if interview with special emphases on the guideline-recommended medications including antiplatelet agents, beta blockers, statins and renin angiotensin blockers.

Official Title
-----------------
Evolution of Risk Factors and Revascularization Among >1 Decade Survivors After Coronary Revascularization in the Middle East

Conditions
-----------------
Risk Factors AND Repeat Revascularization

Intervention / Treatment
-----------------
* Other: risk factors and revascularization procedures


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years or older Coronary stent or bypass 10 years ago or more. Dependable mental status to recall events. Exclusion Criteria: Non coronary operations Inability to recall evnets

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: risk factors and revascularization procedures|arterial revascularizations needed since index procedure|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk factors | Appearance of diabetes, hypertension, smoking, dyslipidemia or obesity since index procedure | Since index procedure to time of interview at least 10 years later | 
| Arterial revascularizations | Undergoing further coronary stent or surgery, carotid stent or surgery, lower limbs stent or surgery, and renal artery stent. | Since index procedure to time of interview at least 10 years later |
Oxycodone vs Fentanyl for Pain Treatment After Laparoscopic Cholecystectomy

Study Overview
=================
Brief Summary
-----------------
To evaluate the analgesic efficacy of oxycodone and fentanyl in the treatment of postoperative pain after laparoscopic cholecystectomy.

Official Title
-----------------
Comparative Study of Oxycodone and Fentanyl Given Intravenously in the Treatment of Early Postoperative Pain After Laparoscopic Cholecystectomy

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: Oxycodone, fentanyl


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Planned outpatient laparoscopic cholecystectomy >18 years Exclusion Criteria: Intolerance to study drugs Treatment with MAO inhibitors

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Oxycodone, fentanyl|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain intensity |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cholecystectomy, postoperative
Effectiveness of Silver Nitrate Solution in the Treatment of Anal Fistula

Study Overview
=================
Brief Summary
-----------------
Effectiveness of silver nitrate solution in treatment of anal fistula is is aimed to be investigated.

Detailed Description
-----------------
The anal fistula is a granulation tissue-lined tract, we thought of a way to ablate this granulation tissue using a chemical agent, which would eventually induce healing with fibrosis and closure of the tract without any surgical intervention. Aiming to reduce the surgery related complications; we investigated the effectiveness of silver nitrate solution as a chemical agent in the treatment of anal fistula.

Official Title
-----------------
Effectiveness of Silver Nitrate Solution in the Treatment of Anal Fistula: A Novel Strategy for Managing Anal Fistula

Conditions
-----------------
Anal Fistula

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with the diagnosis of anal fistula Patients with recurrence Exclusion Criteria: Patients who do not sign the informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Silver Nitrate<br>Irrigation of fistula tract with 1% silver nitrate solution for all patients who accepts the study and signed the written informed consent form. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of anal fistula patients treated with silver nitrate solution. | The primary end point in the study was to assess the efficacy of the silver nitrate in the treatment of anal fistula. The number of anal fistula patients who are treated with silver nitrate solution will be calculated. The role of silver nitrate solution in anal fistula treatment will be investigated | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Therapeutic factors | The secondary end point was to identify the clinical and therapeutic factors that significantly affect the primary endpoint. | 1 year |
Effect of Health Education on Water Handling Practices in Rural Pondicherry

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the drinking water handling practices at household level and to determine the effect of health education on the drinking water handling. Participants from study villages, mainly homemakers, school children and water tank operators who are willing to participate, will be targeted. Baseline assessment of household practices related to water will be done. Followed by a health education regarding the healthy practices will be given to them. Practice of household water chlorination will be promoted. The healthy behavior will be reinforced through reminders and community activities of self help groups for one year. The study participants will be benefited from survey in terms of Improved knowledge and practices of drinking water handling Risk reduction of water borne illness to family members

Official Title
-----------------
Effect of Health Education on Water Handling Practices in Rural Pondicherry

Conditions
-----------------
Drinking Water Handling Practice, Knowledge of Water Borne Diseases, Bacteriological Quality of Water

Intervention / Treatment
-----------------
* Behavioral: Health education


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects of five study villages Exclusion Criteria: Those who anticipate to move out of study area in next one year
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Health education<br>The arm includes all the villages under study. Health education will be provided targeting following groups: 1. Home makers 2. School children 3. Water tank operators. | Behavioral: Health education<br>* Health education will include 1. Importance and demonstration of hygienic practices for safe drinking water 2. Promotion of water purification 3. Capacity building of community for safe water availability.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects following hygienic drinking water handling practices |  | Outcome measure will be assessed at baseline and after one year of health education intervention. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects with improved knowledge and practices related to water borne illnesses |  | Outcome measure will be assessed at baseline and after one year of health education intervention. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Health education, water handling practices, Bacteriological quality of water
Prediction of Childhood Epilepsy Outcome in Bangladesh

Study Overview
=================
Brief Summary
-----------------
Randomised controlled trial of the use of phenobarbitone and carbamazepine in childhood epilepsy in Bangladesh with particular reference to behavioural side effects.

Conditions
-----------------
Epilepsy

Intervention / Treatment
-----------------
* Drug: phenobarbitone
* Drug: carbamazepine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Active epilepsy Aged 2-15 years Exclusion Criteria: Excluded absence Myoclonic and malignant epilepsy syndromes Major motor and cognitive impairments Those currently receiving antiepilepsy drugs.

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: phenobarbitone|nan|
|Drug: carbamazepine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
childhood epilepsy, Active childhood epilepsy
Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia

Study Overview
=================
Brief Summary
-----------------
The purpose of this exploratory study is to evaluate the effects of sertindole and olanzapine on metabolic parameters and syndrome in patients with schizophrenia.

Detailed Description
-----------------
The prevalence of metabolic syndrome is estimated to be around 20-25% of the population and is particularly high in patients with schizophrenia. Individuals with metabolic syndrome are twice as likely to die from, and three times as likely to suffer from a heart attack or stroke compared to individuals without the syndrome. Patients on atypical antipsychotic medication should be considered a high risk group for diabetes and cardiovascular disease. Weight gain is common in patients taking neuroleptics and atypical antipsychotics, and excessive body weight is a risk factor for type 2 diabetes.

Official Title
-----------------
An Exploratory Study Conducted as an add-on to Clinical Trial 11286, to Evaluate the Metabolic Effect of up to 12 Weeks Treatment With Sertindole and Olanzapine in Patients With Schizophrenia

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Drug: Sertindole
* Drug: Olanzapine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with schizophrenia Participation in 11286 study Capable of completing all study-related activities for the duration of the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: Sertindole<br>* 12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days<br>|
| Active Comparator: 2<br> | Drug: Olanzapine<br>* 10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days<br>* Other names: Zyprexa;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes from baseline by treatment and between treatments for each of the components of the metabolic syndrome |  | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Schizophrenia
Dietary Calcium Intake in Premenstrual Syndrome

Study Overview
=================
Brief Summary
-----------------
This study was planned and conducted to investigate effect of adequate calcium intake on Premenstrual Syndrome (PMS) symptoms in women with PMS who have inadequate calcium intake.

Detailed Description
-----------------
This study was planned and conducted to investigate effect of adequate calcium intake on Premenstrual Syndrome (PMS) symptoms in women with PMS who have inadequate calcium intake. Thirty one women, aged between 20-28 years, diagnosed with PMS and suitable for inclusion criteria, were participated in study. Participants were allocated to intervention (n=16) and control (n=15) groups randomly.

Official Title
-----------------
Effect of Sufficient Dietary Calcium Intake in Women With Premenstrual Syndrome

Conditions
-----------------
Premenstrual Syndrome

Intervention / Treatment
-----------------
* Other: Sufficient dietary calcium intake in premenstrual syndrome


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women with; PMS who have inadequate calcium intake Regular menstrual cycle Menstrual flow which occurs every 22 to 35 days and last three to eight days Exclusion Criteria: Having any of metabolic diseases Use oral contraceptive pill user vitamins and minerals supplements being smoker

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 28 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Interventional group<br>8-week follow- up with dietary sufficient calcium intake | Other: Sufficient dietary calcium intake in premenstrual syndrome<br>* Intervention group was ensured to take at least 1000 mg calcium from foods, 700-800 mg of it from dairy and dairy products, according to Recommended Dietary Allowances (RDA), for two months. These foods were; 50 gr kashkaval cheese, 400 ml milk and 150 gr yogurt for each day.<br>|
| No Intervention: Control group<br>8-week follow- up with no specific diet | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Premenstrual Syndrome Scale (PMSS) | Premenstrual Syndrome Scale (PMSS) was used for symptom assessment at initial and after two menstrual cycles. | Eight weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Quality of life scale Short Form (SF-36) |  | Eight weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
premenstrual syndrome, calcium, quality of life
Body Composition Analysis and Time to Emergence From Remimazolam

Study Overview
=================
Brief Summary
-----------------
Remimazolam is a novel general anesthetic drug. The time to emergence from remimazolam-based general anesthesia is variable among patients, but little is known about the risk factors for delayed emergence. We believe that information from body composition analysis may be helpful in understanding which patients are more likely to show delayed emergence from remimazolam.

Official Title
-----------------
Value of Body Composition Analysis in Predicting Delayed Emergence From Remimazolam-based General Anesthesia: A Prospective Observational Study.

Conditions
-----------------
Remimazolam, Body Composition

Intervention / Treatment
-----------------
* Device: body composition analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult ASA I-III patients undergoing cerebral aneurysm coil embolization under general anesthesia using remimazolam Exclusion Criteria: Patients with preoperative mental change, hemodynamic instability, hemodialysis, heart failure, hypoalbuminemia, pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| remimazolam<br>general anesthesia induction with 6mg/kg/hr continuous infusion of remimazolam. general anesthesia maintenance with 1mg/kg/hr continuous infusion of remimazolam. | Device: body composition analysis<br>* Body composition analysis by bioelectrical impedance measurement, just before induction of anesthesia.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| emergence time | relationship between body composition analysis information and time to emergence after discontinuing remimazolam infusion. | at the time of emergence | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time to loss of consciousness | relationship between body composition analysis information and time to loss of consciousness after starting remimazolam infusion. | at the time of induction | 
| hypotension | relationship between body composition analysis information and hypotensive event during anesthesia | from induction to emergence of anesthesia |
Impact of Anti-inflammatory and Antibiotic Therapy on the Emergence of Peri-tonsillar Abscess

Study Overview
=================
Brief Summary
-----------------
Analyze in children and adults, risk factors in the onset of the APA. The main hypothesis focuses on the use of anti-inflammatory in the context of pharyngitis or sore throat before the symptoms of ABS. Secondary objectives: - Analyze the implementation of a rapid diagnostic test and its result on the occurrence of an ABS - Measure the frequency of prescription and describe the reasons for not prescribing an antibiotic for patients who consulted for a sore throat and having developed a PLA - Describe the microbial flora could puncture of patients hospitalized for APA

Official Title
-----------------
Impact of Anti-inflammatory and Antibiotic Therapy on the Emergence of Peri-tonsillar Abscess

Conditions
-----------------
Abscess, Peritonsillar

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical existence of a PLA (phlegmon), validated by a senior ENT, usually (but not necessarily) following a request by an emergency. The visible appearance to the merits throat must justify puncture. Cases will be included whether or not they had consulted for a sore throat in the 10 days preceding the date of diagnosis Exclusion Criteria: Neoplastic disease of the throat, scalable Hematologic with tonsillar localization History of tonsillectomy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| case<br>hospitalized patients, adult or child, including the diagnosis of APA was made, after consulting their physician. | |
| The control group<br>Two patients witnesses will be matched to each case: Chronological criterion: consultation for a sore throat 10 days (± 3 days) before the date of hospitalization of cases, between 13 and J-J-7. Age criteria: year of birth ± 5 years Geographical criteria: living in the same department, failing in an adjacent Department Social criteria: beneficiary or otherwise of the CMU, to avoid a selection bias leading social most frequently at the onset of the APA | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The principal judgement criterion of the study is the positive diagnosis of an APA. The explanatory variables to meet the main objective is the drug exposure (anti-inflammatory) |  | 2,5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The explanatory variables to meet the secondary objectives are: - The creation of a TDR - The prescription of antibiotics - The diagnosis of angina Strep Group A - The identification of a group A streptococcus in t |  | 2,5 years |